ACADIA Pharmaceuticals Inc (ACAD)
15.25
+0.04
(+0.26%)
USD |
NASDAQ |
May 10, 16:00
15.25
0.00 (0.00%)
After-Hours: 18:17
ACADIA Pharmaceuticals Enterprise Value: 2.042B for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 2.042B |
| May 08, 2024 | 2.360B |
| May 07, 2024 | 2.380B |
| May 06, 2024 | 2.338B |
| May 03, 2024 | 2.346B |
| May 02, 2024 | 2.351B |
| May 01, 2024 | 2.346B |
| April 30, 2024 | 2.290B |
| April 29, 2024 | 2.354B |
| April 26, 2024 | 2.290B |
| April 25, 2024 | 2.224B |
| April 24, 2024 | 2.270B |
| April 23, 2024 | 2.295B |
| April 22, 2024 | 2.336B |
| April 19, 2024 | 2.304B |
| April 18, 2024 | 2.345B |
| April 17, 2024 | 2.365B |
| April 16, 2024 | 2.347B |
| April 15, 2024 | 2.316B |
| April 12, 2024 | 2.357B |
| April 11, 2024 | 2.401B |
| April 10, 2024 | 2.454B |
| April 09, 2024 | 2.523B |
| April 08, 2024 | 2.466B |
| April 05, 2024 | 2.500B |
| Date | Value |
|---|---|
| April 04, 2024 | 2.507B |
| April 03, 2024 | 2.568B |
| April 02, 2024 | 2.517B |
| April 01, 2024 | 2.542B |
| March 31, 2024 | 2.580B |
| March 28, 2024 | 2.608B |
| March 27, 2024 | 2.560B |
| March 26, 2024 | 2.492B |
| March 25, 2024 | 2.501B |
| March 22, 2024 | 2.519B |
| March 21, 2024 | 2.595B |
| March 20, 2024 | 2.636B |
| March 19, 2024 | 2.642B |
| March 18, 2024 | 2.646B |
| March 15, 2024 | 2.606B |
| March 14, 2024 | 2.647B |
| March 13, 2024 | 2.784B |
| March 12, 2024 | 2.853B |
| March 11, 2024 | 3.537B |
| March 08, 2024 | 3.423B |
| March 07, 2024 | 3.437B |
| March 06, 2024 | 3.384B |
| March 05, 2024 | 3.484B |
| March 04, 2024 | 3.474B |
| March 01, 2024 | 3.517B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.654B
Minimum
Jun 21 2022
8.384B
Maximum
Dec 01 2020
4.042B
Average
3.439B
Median
Enterprise Value Benchmarks
| Amylyx Pharmaceuticals Inc | -243.93M |
| Regulus Therapeutics Inc | 123.56M |
| Minerva Neurosciences Inc | -17.26M |
| Viking Therapeutics Inc | 7.882B |
| CytomX Therapeutics Inc | -36.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.56M |
| Revenue (Quarterly) | 205.83M |
| Total Expenses (Quarterly) | 190.62M |
| EPS Diluted (Quarterly) | 0.10 |
| Gross Profit Margin (Quarterly) | 88.85% |
| Profit Margin (Quarterly) | 8.04% |
| Earnings Yield | -0.07% |
| Normalized Earnings Yield | -0.0655 |